DE602005025977D1 - Kristalline form des ibandronat-natriums und herstellungsverfahren dafür - Google Patents

Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Info

Publication number
DE602005025977D1
DE602005025977D1 DE602005025977T DE602005025977T DE602005025977D1 DE 602005025977 D1 DE602005025977 D1 DE 602005025977D1 DE 602005025977 T DE602005025977 T DE 602005025977T DE 602005025977 T DE602005025977 T DE 602005025977T DE 602005025977 D1 DE602005025977 D1 DE 602005025977D1
Authority
DE
Germany
Prior art keywords
ibandronate sodium
crystalline form
manufacturing
ray
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005025977T
Other languages
German (de)
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005025977(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602005025977D1 publication Critical patent/DE602005025977D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005025977T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür Expired - Lifetime DE602005025977D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (1)

Publication Number Publication Date
DE602005025977D1 true DE602005025977D1 (de) 2011-03-03

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005025977T Expired - Lifetime DE602005025977D1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
DE202005021414U Expired - Lifetime DE202005021414U1 (de) 2004-08-23 2005-08-23 Festes und kristallines Ibandronat-Natrium

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE202005021414U Expired - Lifetime DE202005021414U1 (de) 2004-08-23 2005-08-23 Festes und kristallines Ibandronat-Natrium

Country Status (12)

Country Link
US (1) US7563918B2 (https=)
EP (2) EP1930011B1 (https=)
JP (1) JP4559431B2 (https=)
KR (2) KR20090120011A (https=)
CN (1) CN101022812A (https=)
AT (2) ATE495747T1 (https=)
CA (1) CA2576659A1 (https=)
DE (2) DE602005025977D1 (https=)
ES (1) ES2358269T3 (https=)
IL (1) IL181298A (https=)
PT (2) PT1930011E (https=)
WO (1) WO2006024024A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3395338T (pt) 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
EP2363401A1 (en) * 2005-02-01 2011-09-07 F. Hoffmann-La Roche AG Ibandronate polymorph B
RU2368617C2 (ru) * 2005-02-01 2009-09-27 Ф.Хоффманн-Ля Рош Аг Полиморфная модификация а ибандроната
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
EP2009016A3 (en) 2006-11-16 2009-02-25 Teva Pharmaceutical Industries Ltd Process for preparing crystalline form of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
BRPI0809548A8 (pt) 2007-04-11 2018-10-16 Hoffmann La Roche processo para a preparação do sal ácido- (mono-hidratado)-3- (n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfônico monossódico
AU2008242788A1 (en) 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2212338B1 (en) * 2007-10-26 2013-07-10 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
EP2429390B1 (en) 2009-05-15 2015-09-09 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
ES2525844T3 (es) 2010-06-25 2014-12-30 Nox Medical Ehf. Conector para correa biométrica
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
WO2015068041A1 (en) 2013-11-06 2015-05-14 Nox Medical Method, apparatus, and system for measuring respiratory effort
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2018033889A1 (en) 2016-08-19 2018-02-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
US11896386B2 (en) 2017-06-02 2024-02-13 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
WO2019049097A1 (en) 2017-09-08 2019-03-14 Nox Medical Ehf SYSTEM AND METHOD FOR NON-INVASIVE DETERMINATION OF AN INTERNAL COMPONENT OF RESPIRATORY EFFORT

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ATE314862T1 (de) * 2000-05-05 2006-02-15 Hoffmann La Roche Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
CA2410201C (en) * 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
TWI282283B (en) * 2002-05-17 2007-06-11 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
HRP20041013B1 (hr) * 2002-12-20 2013-10-25 F. Hoffmann - La Roche Ag Formulacija visoke doze ibandronata
CA2551230A1 (en) * 2003-12-23 2005-07-14 Lyogen Limited A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP2363401A1 (en) 2005-02-01 2011-09-07 F. Hoffmann-La Roche AG Ibandronate polymorph B
RU2368617C2 (ru) 2005-02-01 2009-09-27 Ф.Хоффманн-Ля Рош Аг Полиморфная модификация а ибандроната
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
KR20090120011A (ko) 2009-11-23
EP1930011A2 (en) 2008-06-11
IL181298A (en) 2011-04-28
CA2576659A1 (en) 2006-03-02
PT1930011E (pt) 2011-09-16
EP1713489A2 (en) 2006-10-25
IL181298A0 (en) 2007-07-04
DE202005021414U1 (de) 2008-03-20
CN101022812A (zh) 2007-08-22
EP1930011B1 (en) 2011-08-17
ATE495747T1 (de) 2011-02-15
WO2006024024A2 (en) 2006-03-02
JP4559431B2 (ja) 2010-10-06
ATE520406T1 (de) 2011-09-15
EP1930011A3 (en) 2008-06-18
PT1713489E (pt) 2011-03-03
JP2007512237A (ja) 2007-05-17
KR20070043043A (ko) 2007-04-24
US7563918B2 (en) 2009-07-21
WO2006024024A3 (en) 2006-06-29
US20070179119A1 (en) 2007-08-02
ES2358269T3 (es) 2011-05-09
EP1713489B1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
DE602005025977D1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
MY145696A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-menthyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
TW200716558A (en) Heteroaroyl-substituted serineamides
IL190137A (en) Lacquinimod crystalline mixtures, pharmaceutical compositions containing them and ways to prepare them
BG107532A (en) Novel alpha chrystalline form of perindopril tert-butylamine salts, preparation method and pharmaceutical compositions containing same
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
TW200738241A (en) Pyridazine derivatives
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MY151295A (en) Pyrimidyl indoline compound
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY142856A (en) New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
CO5560555A2 (es) Cristales de derivado de hidroxinorefedrina
TW200740764A (en) Pyrazolone derivatives
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
TW200800993A (en) Organic compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
TW200613279A (en) New pesticides
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
TW200730498A (en) Compounds
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
MY138209A (en) New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it.
TW200738606A (en) Thioamide compounds for combating animal pest
MY144456A (en) Pesticidal agents on the basis of 1-aryl-aminopyrrol